Candida auris is a multidrug-resistant fungal pathogen that presents a serious threat to
global human health. Since the first reported case in 2009 in Japan, C. auris infections have …

Systemic fungal infections pose a serious clinical problem. Treatment options are limited,
and antifungal drug resistance is increasing. In addition, a substantial proportion of patients …

Background The emergence of antifungal resistance threatens effective treatment of
invasive fungal infection (IFI). Invasive candidiasis is the most common health care …

With increasing number of immunocompromised patients as well as drug resistance in fungi,
the risk of fatal fungal infections in humans increases as well. The action of echinocandins is …

Invasive Candida infections remain an important cause of morbidity and mortality, especially
in hospitalized and immunocompromised or critically ill patients. A limited number of …

New antifungal drugs are urgently needed to address the emergence and transcontinental
spread of fungal infectious diseases, such as pandrug-resistant Candida auris. Leveraging …

We reviewed the licensed antifungal drugs and summarized their mechanisms of action,
pharmacological profiles, and susceptibility to specific fungi. Approved antimycotics inhibit 1 …

Candida parapsilosis is the second most common Candida species isolated in Asia,
Southern Europe, and Latin America and is often involved in invasive infections that …

Patients with suppressed immunity are at the highest risk for hospital-acquired infections.
Among these, invasive candidiasis is the most prevalent systemic fungal nosocomial …

The high rates of morbidity and mortality caused by fungal infections are associated with the
current limited antifungal arsenal and the high toxicity of the compounds. Additionally …